|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.03.26 - 21:06
|
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance (Business Wire)
|
|
|
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026.
Recent Highlights
Fourth quarter 2025 net revenues grew 23% to $10.9 million; Full year 2025 net revenues grew 22% to $41.1 million
Full year 2025 gross profit grew 20% to $25.6 million with gross margin of 62.3%
Full year 2025 net loss of ($2.6) million, a 57% improvement over the prior year and a 124% increase in positive adjusted EBITDA to $0.6 million
Ending cash balance of $8.9 million, representing annual cash usage of $0.7 million, a 63% improvement versus the prior year
Received 510(k) clearance for UCB RYSTIGGO®, further expanding the KORU Medical pla...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
